Key Highlights
- Third-quarter 2026 total revenues were USD 18.7 million, against USD 53.0 million.
- Royalty Revenue under the Incyte license was USD 8.6 million, against USD 3.3 million.
- Net loss for the quarter was USD 20.1 million.
- The company says its cash supports a cash runway through 2028.
MacroGenics (NASDAQ:MGNX) reported third-quarter 2026 total revenues of USD 18.67 million, against an estimate of USD 39.18 million. Loss per share was USD 0.32, in line with the estimate of USD 0.32. The clinical-stage biopharmaceutical company develops antibody-based therapeutics, including MGC026, MGC028, MGC030 and MGD032.
The filing shows total revenues of USD 18,667 thousand for the quarter, against USD 53,003 thousand a year earlier, and USD 58,220 thousand for the nine months, against USD 66,915 thousand.
Revenue
Revenue from license, milestone and other agreements was USD 10,085 thousand in the quarter, against USD 49,670 thousand. Royalty revenue was USD 8,582 thousand, against USD 3,333 thousand, and USD 22,078 thousand for the nine months, against USD 5,087 thousand. The filing says the company recognized USD 8.6 million and USD 22.1 million of royalty revenue under the Incyte License Agreement for the three and nine months.
Revenue from the Incyte Commercial Supply Agreement is reflected in Net Income from discontinued operations. The company recognized no such revenue in the third quarter of 2026, against USD 1.0 million in the third quarter of 2025, and USD 14.4 million for the nine months, against USD 1.7 million. The filing also notes that the nine-month 2026 period included proceeds of USD 119,572 thousand from the sale of the company's CDMO operations.
Expenses and Net Loss
Research and development expenses were USD 30,610 thousand, against USD 32,709 thousand, and USD 104,363 thousand for the nine months, against USD 113,198 thousand. The filing says decreases were partly offset by increased Manufacturing and clinical trial costs related to MGC026 and MGC028, increased clinical trial costs related to MGC030 and MGD032, and increased development costs related to certain next generation T-cell engagers.
General and administrative expenses were USD 8,360 thousand, against USD 9,905 thousand. Total costs and expenses were USD 38,970 thousand, against USD 42,614 thousand. The loss from operations was USD 20,303 thousand, against income from operations of USD 10,389 thousand. Interest and other income was USD 2,912 thousand, against USD 1,528 thousand.
Net loss was USD 20,076 thousand for the third quarter. For the nine months, the loss from operations was USD 72,118 thousand, and the results included a loss on extinguishment of the royalty monetization Liability of USD 52,762 thousand. Total stockholders' Equity was USD 25,151 thousand at September 30, 2026.
Cash Flow and Runway
Net cash used in Operating Activities was USD 82,890 thousand for the nine months, against USD 124,061 thousand. Purchases of marketable securities were USD 263,982 thousand, and proceeds from maturities of marketable securities were USD 159,778 thousand. Net cash provided by investing activities was USD 14,146 thousand, against cash used of USD 48,107 thousand.
The filing states that the company's cash, cash equivalents and marketable securities as of September 30, 2026, combined with projected future payments from partners and savings from ongoing cost-reduction initiatives, support its cash runway through 2028. It says the company has implemented, and continues to evaluate, cost-saving measures intended to extend its runway while continuing to progress its pipeline.






Please wait processing your request...